Oral Budesonide for Inflammatory Bowel Disease Treatment

Treatment Recommendations

The European Crohn's and Colitis Organisation recommends budesonide MMX 9 mg daily as an alternative to conventional steroids for patients with mild to moderate ulcerative colitis who have an inadequate response to mesalazine therapy 1
Budesonide MMX is particularly effective for left-sided disease, but less effective for extensive colitis, according to the European Crohn's and Colitis Organisation 1, 2
For mild to moderate ileocecal Crohn's disease, the American Gastroenterological Association recommends oral budesonide 9 mg/day as first-line therapy 3, 4

Budesonide MMX 9 mg/day has shown 8-week combined clinical and endoscopic remission rates of 20.3% vs 3.2% for placebo, with a moderate strength of evidence 1, 2
Endoscopic healing rates were 27.6% vs 17.1% for budesonide MMX and placebo, respectively, according to the Journal of Crohn's and Colitis 2
A randomized trial showed budesonide MMX 9 mg/day induced clinical, endoscopic, and histological remission more frequently than placebo in patients inadequately controlled with oral 5-ASA, with a high strength of evidence 2

Patients should be evaluated for symptomatic response to budesonide between 4 and 8 weeks to determine the need to modify therapy, as recommended by the Clinical Gastroenterology and Hepatology society 4
Budesonide should not be used for maintenance therapy as it is ineffective for this indication and prolonged use is associated with significant adverse effects, according to the Clinical Gastroenterology and Hepatology society 4

The British Society of Gastroenterology strongly recommends budesonide MMX as an alternative first-line therapy to induce complete remission in patients with mild to moderate UC of any disease extent 5
For ileocecal Crohn's disease, ileal-release budesonide 9 mg once daily for 8 weeks is recommended to induce remission, with tapering over 1-2 weeks after remission is achieved 6, 7

Patients should be evaluated for lack of symptomatic response to corticosteroid induction therapy within 2 weeks to determine the need to modify therapy 8, 9
For mild to moderate ileocecal Crohn's disease, patients should be evaluated for symptomatic response to budesonide between 4 and 8 weeks 10
If a patient shows inadequate response to budesonide MMX, alternative therapies should be considered rather than extending the treatment duration beyond 8 weeks 5

Budesonide should not be used for maintenance therapy in UC as corticosteroids are ineffective for this indication and prolonged use is associated with significant adverse effects 8, 9
In patients with Crohn's disease, guidelines specifically recommend against the use of oral budesonide to maintain complete remission 10
Abrupt discontinuation rather than tapering after achieving remission may lead to symptom recurrence 7
Using budesonide for maintenance therapy is not recommended and may expose patients to unnecessary risks 8, 10
Failure to monitor for lack of response within 2 weeks may delay necessary treatment modifications 8

For patients with moderate ulcerative colitis, if there is an inadequate response to treatment after 2 weeks of oral corticosteroids, consider escalating to advanced therapies (biologics or small molecules) 11, 12